[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100598101":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":25,"centralContacts":29,"locations":35,"responsibleParty":53,"collaborators":24,"id":55,"slug":56,"hasResults":57,"nctId":58,"briefTitle":59,"officialTitle":59,"acronym":60,"eligibilityCriteria":61,"healthyVolunteers":62,"sex":63,"minAge":64,"maxAge":65,"enrollmentInfo":66,"targetDuration":24,"studyType":69,"phases":70,"briefSummary":72,"conditions":73,"keywords":75,"overallStatus":80,"whyStopped":24,"lastUpdateSubmitDate":81,"lastUpdatePostDateStruct":82,"startDateStruct":85,"completionDateStruct":87,"leadSponsor":89,"locationsCount":90},{"fullName":5,"class":6},"University Hospital, Clermont-Ferrand","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Chronic migraine","EXPERIMENTAL","Chronic migraine patients will donate 100 milliliters (mL) of peripheral and venous blood, answer a questionnaire and 2 phone calls (one at day 1 and the other at day 3 from the blood test).",[13],"Biological: Blood sampling, questionnaire and phone call",{"label":15,"type":10,"description":16,"interventionNames":17},"Controls","Non-migraine controls will donate 100 mL of peripheral and venous blood, answer a questionnaire and 2 phone calls (one at day 1 and the other at day 3 from the blood test).",[13],[19],{"type":20,"name":21,"description":22,"armGroupLabels":23,"otherNames":24},"BIOLOGICAL","Blood sampling, questionnaire and phone call","The blood sample will drawn after a fasting period of at least 8 hours, and the questionnaire will be auto-administered",[9,15],null,[26],{"name":27,"affiliation":5,"role":28},"Xavier MOISSET","PRINCIPAL_INVESTIGATOR",[30],{"name":31,"role":32,"phone":33,"phoneExt":24,"email":34},"Lise Laclautre","CONTACT","334.73.754.963","promo_interne_drci@chu-clermontferrand.fr",[36],{"facility":37,"status":24,"city":38,"state":24,"zip":24,"country":39,"countryCode":40,"cosmosGeoPoint":41,"geoPoint":46,"contacts":47},"CHU Clermont-Ferrand","Clermont-Ferrand","France","FR",{"type":42,"coordinates":43},"Point",[44,45],3.08682,45.77969,{"lat":45,"lon":44},[48,52],{"name":49,"role":32,"phone":50,"phoneExt":24,"email":51},"Lise LACLAUTRE","0473754963","llaclautre_perrier@chu-clermontferrand.fr",{"name":27,"role":28,"phone":24,"phoneExt":24,"email":24},{"type":54,"investigatorFullName":24,"investigatorTitle":24,"investigatorAffiliation":24,"oldNameTitle":24,"oldOrganization":24},"SPONSOR","100598101","suppressive-functions-of-regulatory-t-cells-in-migraine-100598101",false,"NCT07067112","Suppressive Functions of Regulatory T Cells in Migraine","SIIM-reg","Inclusion Criteria:\n\n* Females\n* 18 to 50 years old\n* Chronic migraine participants : chronic migraine (at least 15 days of headache\u002Fmonth, according to the International Classification of Headache Disorders, 3rd edition criteria\n\nExclusion Criteria:\n\n* BMI \\\u003C or = 17kg\u002Fm² or \\> or = 30kg\u002Fm²\n* Diagnosis or suspicion of type 2 diabetes, auto-immune or inflammatory diseases, immunodeficiency diseases\n* Diagnosis of headache of non-migraine origin, except for tension type headache \\\u003C or = 4 days per month (i.e.: cluster headache, post-traumatic headache, cerebral tumour…)\n* Pregnancy, delivery, miscarriage, breastfeeding, participation in a medically assisted human reproduction program (ovary stimulation\u002Fhormone therapy) \\\u003C 3 months before blood sampling\n* Menopause, hysterectomy, or bilateral oophorectomy\n* Flare of the autoimmune\u002Finflammatory disease of interest \\\u003C 1 month before blood sampling\n* Modification of maintenance therapy for the autoimmune\u002Finflammatory disease of interest (start, change of molecule, interruption) \\\u003C 3 months before blood sampling\n* Modification of prophylactic anti-migraine therapy (start, change of molecule, interruption) \\\u003C 3 months before blood sampling (for migraine participants)\n* Hormone therapy (besides contraception and treatment of endometriosis)\n* Transplantation (solid organ or bone marrow)\n* Cancer (active or remitting) \\\u003C 1 year before blood sampling (solid organ or blood)\n* Haematologic disease (benign or malignant) of the lymphoid lineage\n* Guardianship, curatorship, safeguard of justice or deprivation of liberty\n* For controls : diagnosis of migraine",true,"FEMALE","18 Years","50 Years",{"count":67,"type":68},24,"ESTIMATED","INTERVENTIONAL",[71],"NA","Migraine is a frequent, disabling condition, of great social and economical impact worldwide. This condition is more frequent in women and subjects with autoimmune and\u002For inflammatory diseases. Cytokine and immune cell dysregulations have been evidenced in migraine. Inflammation seems to play an important role in migraine chronification; however, the inflammatory mechanisms involved in migraine pathophysiology remain unclear. Regulatory T (Treg) cells play a central role in maintaining immune homeostasis. They regulate effector T (Teff) cell proliferation and cytokine production, through several suppressive mechanisms, such as the hydrolysis of adenosine triphosphate (ATP) into adenosine (ADO), mediated by surface enzymes Cluster Differentiation 39 (CD39) and Cluster Differentiation 73 (CD73). ATP is involved in pain processes in migraine, and insufficient hydrolysis could participate in pain chronification. Recent studies suggest altered proportions of Treg cells in migraine, and decreased levels of CD39-positive (CD39+) Treg cells, suggesting Treg suppressive functions may be decreased in the disease. However, there have been no functional studies to date to confirm this hypothesis.\n\nThe investigators believe Treg suppressive functions may be decreased in migraine, and that such alterations may be caused by a malfunction in the ADO pathway.",[74],"Chronic Migraine",[76,77,78,79],"Migraine","Inflammation","Immune system","Regulatory T cells","NOT_YET_RECRUITING","2026-06-18",{"date":83,"type":84},"2026-06-22","ACTUAL",{"date":86,"type":68},"2026-07-01",{"date":88,"type":68},"2027-11-30",{"name":5,"class":6},1]